Akt is a serine/threonine protein kinase that is activated by a variety of growth factors or cytokines in a phosphatidylinositol 3-kinase-dependent manner. By using a conditional transgenic system in which Akt signaling can be turned on or off in the adult heart, we previously showed that short-term Akt activation induces a physiological form of cardiac hypertrophy with enhanced coronary angiogenesis and maintained contractility. Here we tested the hypothesis that induction of physiological hypertrophy by short-term Akt activation might improve contractile function in failing hearts. When Akt signaling transiently was activated in murine hearts with impaired contractility, induced by pressure overload or doxorubicin treatment, contractile dysfunction was attenuated in both cases. Importantly, improvement of contractility was observed before the development of cardiac hypertrophy, indicating that Akt activation improves contractile function independently of its growth-promoting effects. To gain mechanistic insights into Akt-mediated positive inotropic effects, transcriptional profiles in the heart were determined in a pressure overload-induced heart failure model. Biological network analysis of differentially expressed transcripts revealed significant alterations in the expression of genes associated with cell death, and these alterations were reversed by short-term Akt activation. Thus, short-term Akt activation improves contractile function in failing hearts. This beneficial effect of Akt on contractility is hypertrophy-independent and may be mediated in part by inhibition of cell death associated with heart failure. 
Akt is a serine/threonine protein kinase that is activated by a variety of growth factors or cytokines in a phosphatidylinositol 3-kinase-dependent manner. By using a conditional transgenic system in which Akt signaling can be turned on or off in the adult heart, we previously showed that short-term Akt activation induces a physiological form of cardiac hypertrophy with enhanced coronary angiogenesis and maintained contractility. Here we tested the hypothesis that induction of physiological hypertrophy by short-term Akt activation might improve contractile function in failing hearts. When Akt signaling transiently was activated in murine hearts with impaired contractility, induced by pressure overload or doxorubicin treatment, contractile dysfunction was attenuated in both cases. Importantly, improvement of contractility was observed before the development of cardiac hypertrophy, indicating that Akt activation improves contractile function independently of its growth-promoting effects. To gain mechanistic insights into Akt-mediated positive inotropic effects, transcriptional profiles in the heart were determined in a pressure overload-induced heart failure model. Biological network analysis of differentially expressed transcripts revealed significant alterations in the expression of genes associated with cell death, and these alterations were reversed by short-term Akt activation. Thus, short-term Akt activation improves contractile function in failing hearts. This beneficial effect of Akt on contractility is hypertrophy-independent and may be mediated in part by inhibition of cell death associated with heart failure. Heart failure is a major cause of mortality and morbidity worldwide. [1] [2] [3] [4] One common feature of heart failure is hypertrophy of individual cardiac muscle cells in the myocardium. [5] [6] [7] [8] Cardiac hypertrophy observed in patients with hypertension, myocardial infarction, or valvular heart disease is considered to be an adaptive response because hypertrophy can normalize the increase in wall stress induced by mechanical overload. However, increased cardiac mass is clinically associated with increased morbidity and mortality, 9 and sustained overload eventually leads to contractile dysfunction and heart failure. 10 -12 Thus, stress-induced or pathologic cardiac hypertrophy appears to be detrimental for the heart. Conversely, normal postnatal growth of the heart or exerciseinduced cardiac growth also occurs through hypertrophy of individual cardiac muscle cells. These forms of socalled physiological cardiac hypertrophy are associated with normal or enhanced contractile function and are morphologically and molecularly distinct from stress-induced hypertrophy. 13, 14 Akt is a serine/threonine protein kinase that mediates cellular growth responses in multiple organisms and cell types. 15, 16 There are three Akt genes in mammalian genomes (Akt1/PKB␣, Akt2/PKB␤, and Akt3/PKB␥). Loss of Akt1 gene in mice leads to general growth retardation and spontaneous apoptosis in restricted cell types. knockout mice show a selective growth defect of the brain. 21, 22 Furthermore, these genes display a considerable degree of functional overlap, exemplified by the combined deletion of Akt1 and Akt2 genes, which results in perinatal lethality with severe growth retardation and multiple developmental defects 23 and by Akt1/Akt3 double-knockout mice, which are embryonic-lethal owing to a placental defect. 24 In the heart, Akt is an important positive regulator of normal postnatal cardiac growth 25 and also is activated by exercise training, 26 -28 by pressure overload, 29 and is activated in diseased human hearts. 30 Overexpression of activated Akt1 or Akt3 in the heart is sufficient to induce cardiac hypertrophy and, in some cases, heart failure in transgenic (TG) mice. [31] [32] [33] [34] These data suggest that Akt-dependent signaling pathways are involved in both physiologic and pathologic cardiac growth.
By using a conditional TG system, in which the expression of the Akt transgene can be turned on or off at desired time points, we previously showed that shortterm Akt activation induces physiologic hypertrophy but long-term Akt activation leads to pathologic hypertrophy and heart failure. 35 In cardiac hypertrophy induced by short-term Akt activation, contractile function was preserved. Because physiologic hypertrophy can be adaptive by reducing wall stress without adverse effects on contractile function, we tested the hypothesis that induction of physiologic hypertrophy by shortterm Akt activation might attenuate contractile dysfunction in failing hearts. We show that transient Akt activation improves contractile function in two different heart failure models and we explored the potential mechanisms of Akt-mediated positive inotropic effects by transcriptome analysis.
Materials and Methods

Animals
Generation, genotyping, and the initial characterization of cardiac-specific inducible Akt TG mice have been described previously. 35 In brief, two lines of TG mice (tetAkt and ␣MHC-tTA) were crossed to generate double-TG (DTG) mice. When DTG mice are treated with doxycycline (DOX), the expression of Akt transgene is turned off. When DOX is withdrawn, Akt transgene expression is induced specifically in the heart. ␣MHC-tTA single-TG mice were used as controls and treated with DOX in the same manner as DTG animals.
Heart Failure Models
For pressure overload-induced heart failure models, mice were subjected to ascending aorta constriction (AAC) at the age of 8 weeks as described previously. 36 DOX was withdrawn at the age of 12 weeks (4 weeks after AAC) to induce Akt transgene expression in the heart. DOX had been given continuously since before birth. Echocardiography was performed at the age of 8 (before AAC), 12 (4 weeks after AAC), 13 (1 week after Akt activation), and 14 weeks (2 weeks after Akt activation). For Adriamycin (ADR; Sigma-Aldrich, St. Louis, MO)-induced heart failure models, ADR was administered to 12-week-old mice in 3 equal intraperitoneal injections for 2 weeks (8 mg/kg for a single injection, cumulative dose of 24 mg/kg body weight). DOX was withdrawn at the age of 16 weeks (4 weeks after initial ADR injection) to induce Akt transgene in the heart. DOX had been given continuously since before birth. Echocardiography was performed at the age of 12 (before ADR injection), 16 (4 weeks after initial ADR injection), 17 (1 week after Akt activation), and 18 weeks (2 weeks after Akt activation).
Echocardiography
Transthoracic echocardiography was performed with an ACUSON 256 sector scanner (Siemens, Mountain View, CA) equipped with a 13-MHz transducer as described previously. 35 
Microarray Analysis
Transcriptional profiles were determined in pressure overload-induced heart failure models. Mice were sacrificed at predetermined time points. Hearts were excised and snap-frozen in liquid nitrogen. RNA extraction, cDNA synthesis, biotinylated cRNA preparation, and hybridization of cRNA to microarrays (GeneChip Mouse Expression Set 430; Affymetrix, Santa Clara, CA) were performed as described. [37] [38] [39] Data were obtained at three time points [before AAC, 4 weeks after AAC, and 6 weeks after AAC (2 weeks after Akt activation)], and four independent sets of hybridizations were performed at each time point. An automated analysis of related transcripts was performed using Ingenuity Pathways Analysis (Redwood City, CA), a webdelivered application that evaluates biological networks. Data analysis was performed as described. [37] [38] [39] In addition, automated analysis of groups of biologically related genes was performed using GenMAPP and MAPPFinder version 2.0 (http://www. genmapp.org) as described. 37 MAPPFinder is a tool that integrates the annotations of the Gene Ontology Project (http://www.geneontology.org) with the free software package Gen-MAPP. MAPPFinder identifies Gene Ontology Project terms with overrepresented numbers of gene-expression charges. GenMAPP generates graphic files within which gene expression data can be viewed in the context of the biological knowledge contained in the Gene Ontology Project database.
qPCR Analysis
Expression levels of selected transcripts were examined by quantitative real-time PCR (qPCR) as described. 37 The primers in Table 1 were used for qPCR analysis.
Results
Improvement of Contractile Function by Transient Akt Activation
To examine the effects of inducible Akt activation in failing hearts, mice were subjected to AAC at the age of 8 weeks and Akt transgene was induced by withdrawing DOX at the age of 12 weeks, when contractile dysfunction was apparent by echocardiography ( Figure 1 ). At the age of 13 weeks (1 week after Akt activation), there was a significant increase in the percentage of fractional shortening in DTG animals compared with control animals. This improvement of contractility was maintained at 14 weeks of age (2 weeks after Akt activation). Of note, there was a significant increase in posterior wall thickness in DTG mice compared with control animals at 14 weeks old but not at 13 weeks old. This is consistent with our previous observation that a significant increase in heart weight starts to be observed at day 10 after Akt transgene induction. 35 These findings indicate that transient Akt activation in failing hearts leads to improvement of contractile function, and this positive inotropic effect of Akt activation is independent of its growth-promoting effect.
To examine whether this beneficial effect of Akt on contractility is observed in a different form of heart failure, Akt transiently was activated in failing hearts induced by ADR treatment. Mice received three injections of ADR once a week beginning at the age of 12 weeks. Akt transgene was induced by withdrawing DOX at the age of 16 weeks (Figure 2 ). At this time point, contractile dysfunction was apparent by echocardiography. As was the case with pressure overload-induced heart failure, transient Akt activation in cardiac muscle cells improved ADR-induced contractile function, and this beneficial effect of Akt was independent of its growth-promoting effect because there was a significant increase in the percentage of fractional shortening at the age of 17 weeks (1 week after Akt activation) when there was no increase in wall thickness. Taken together, Akt activation improves contractile function in two different models of heart failure independently of its growth-promoting effect on the myocardium.
Microarray Analysis of Differentially Expressed Genes
To gain insights into Akt-mediated, positive inotropic effects, transcriptional profiles in the heart were determined in a pressure overload-induced heart failure model. RNA samples were prepared at 8 weeks (time point 1: before AAC), 12 weeks (time point 2: 4 weeks after AAC when there is apparent contractile dysfunction), and 14 weeks Table 1 . qPCR Analysis. Expression levels of selected transcripts were examined by qPCR as described. 37 
Transcript
Forward primer Reverse primer 5'-GAAGGACCGCAGAAAGAAGCT-3' 5'-GTTCGGATTCCTGTCTCATCTCA-3' Mitogen activated protein kinase 13
Akt Improves Contractility 1971 AJP December 2012, Vol. 181, No. 6 (time point 3: 2 weeks after Akt activation, when contractile function has been improved), and transcriptome analysis was performed. When time points 1 and 2 were compared, 381 genes differentially were regulated, of which 212 were up-regulated and 169 were down-regulated. When time points 2 and 3 were compared, 328 genes differentially were regulated, of which 162 genes were up-regulated and 166 genes were down-regulated ( Figure 3A) . Venn diagram analysis revealed that the expression of 619 transcripts differentially were regulated, of which 291 genes differentially were regulated only when heart failure was developing, 238 genes differentially were regulated only when heart failure was improving, and 90 genes differentially were regulated during both of these processes ( Figure 3B ). Differential expression of genes with a fold change more than ϩ2.0 or less than Ϫ2.0 with a P value less than 0.01 were confirmed by qPCR and are listed in Tables 2 and 3 . Categorization of differentially regulated genes using Gene Ontology Analysis revealed that genes associated with cell death and tissue development were up-regulated during heart failure progression, which was attenuated by Akt activation. Conversely, genes associated with cancer, carbohydrate metabolism, and cell cycle were up-regulated when heart failure was improving by Akt activation ( Figure 3C ). Biological network analysis of differentially expressed transcripts performed using Ingenuity Pathways Analysis revealed a set of genes, categorized as cell "death network," with significant alterations in the expression levels at 12 weeks of age, 4 weeks after AAC, when there is apparent contractile dysfunction (see Supplemental Figure S1 at http://ajp.amjpathol.org). After 2 weeks of Akt activation, these alterations in the expression levels of a specific set of genes were attenuated or in some cases reversed (see Supplemental Figure S2 at Table  S1 (available at http://ajp.amjpathol.org). Taken together, categorization and biological network analysis suggest that alterations in the expression levels of genes associated with cell death may be involved in the positive inotropic effects of Akt activation in the setting of heart failure.
Discussion
Unlike pathologic cardiac hypertrophy observed in patients with hypertension or valvular heart diseases, physiologic cardiac hypertrophy as observed in trained athletes or during normal postnatal growth is associated with maintained or enhanced contractile function. By using an inducible TG system in which cardiac Akt signaling can be turned on or off at desired time points, we previously showed that short-term Akt activation in the adult heart induces a physiologic form of cardiac hypertrophy. 35 Because cardiac hypertrophy can be beneficial for the heart through reduction of wall stress, we hypothesized that physiologic hypertrophy induced by shortterm Akt activation might improve contractile function in failing hearts. To test this hypothesis, we used two different murine heart failure models (pressure overload-or ADR-induced heart failure models) and showed that transient Akt activation after the establishment of heart failure improved contractility in both cases. This experiment is relevant because it mimics the clinical situation in which therapeutic intervention is started after the onset of heart failure, and has been difficult to perform with conventional knockout or TG mice in which deletion or overexpression of a specific gene is initiated during early embryogenesis. It was rather unexpected, however, that the transient Akt activation attenuated contractile dysfunction at earlier time points when no apparent hypertrophy was observed. This clearly indicates that the beneficial effect of Akt on contractility is independent of its effect to promote physiologic cardiac hypertrophy. Thus, although transient Akt activation does improve contractile function in the failing heart, this improvement is not caused by a reduction in wall stress by Akt-mediated physiologic hypertrophy. Of note, short-term Akt activation does not affect contractile function when Akt is turned on in normal hearts, 35 indicating that the beneficial effect of Akt is specific to failing hearts. This raises the question as to the mechanism by which transient Akt activation has positive inotropic effects in the setting of heart failure.
Previous studies have associated Akt activation with pathologic cardiac hypertrophy. It recently was shown in the canine congestive heart failure/cardiac recovery model that phosphatidylinositol 3K␥ and phosphatidylinositol 3K␣ expressions increase during the congestive heart failure and cardiac recovery phases, respectively. 40 The study went on to extrapolate that, based on the measured increase of phosphatidylinositol 3K␣/Akt during the experimental recovery phase, the phosphatidylinositol 3K␣/Akt signaling pathway potentially plays a role in compensatory cardiac hypertrophy. However, this and other studies linking Akt and pathologic cardiac hypertrophy generally were based on constitutively active forms of the Akt pathway. In contrast, our model indicates that contractile improvements after heart failure may not be completely linked with hypertrophic growth, as evidenced by the lack of hypertrophy (heart rate/body weight) seen in our model. We do recognize, however, that any direct comparison of experimental results must be viewed with caution because of differences in the experimental models. Therefore, echocardiography was chosen as an outcome marker because it is a well-established technique for measuring cardiac function and thus allows our work to be compared directly with previous works in which cardiac recovery was associated with hypertrophy.
In our previous study, we showed that short-term Akt activation enhances vascular endothelial growth factor secretion from the myocardium and promotes coronary angiogenesis, which is required for the maintenance of cardiac function during Akt-induced physiologic heart growth: blocking the vascular endothelial growth factor signal during short-term Akt activation results in early transition from physiologic to pathologic hypertrophy and contractile dysfunction. 35 It also has been shown that myocardial capillary density is decreased in hearts subjected to pressure overload. 41 Therefore, one possible explanation for the Akt-mediated positive inotropic effect is that Akt induces vascular endothelial growth factor expression in cardiac muscle cells, thereby increasing the otherwise reduced capillary density in failing hearts. A second possibility is that Akt modulates Ca 2ϩ handling in cardiac myocytes and enhances contractility. It has been shown that Akt increases the protein expression levels of sarcoplasmic reticulum calcium ATPase 2 (SERCA2) in TG mice overexpressing constitutively active Akt 42 or in rat hearts infected with Akt adenoviruses. 43 Because overexpression of SERCA2 has been shown to improve contractile function in heart failure models, 44 Akt may show positive inotropic effects by increasing the expression levels of SERCA2. Previous investigations, 45 among others, have shown a link between activation of the phosphatidylinositol 3K/Akt pathway and SERCA2a regulation. Although the scope of our investigations did not specifically include measurements of SERCA2a or other calcium-regulating proteins, it seems more than likely that in light of the aforementioned investigations, Akt-dependent regulation of SERCA2a is a potential mechanism for affecting myocyte contractility. Moreover, the potential mechanisms responsible for our model's improved cardiac contractility will be the subject of our next series of investigations. A third possibility suggested by our transcriptome analysis is that Akt improves contractile function by suppressing cell death in the failing heart. Several lines of evidence support the notion of a causal role of apoptosis in heart failure. It was shown that even low levels of cardiomyocyte apoptosis, induced by procaspase-8, led to lethal dilated cardiomyopathy in TG mice, and that this phenotype was prevented by treatment with caspase inhibitor. 46 Caspase inhibitor treatment also ameliorated the development of heart failure in G␣q TG mice. 47 Moreover, loss of gp130-mediated cell survival signals led to early transition from adaptive cardiac growth to heart failure in response to pressure overload. 48 Given that Akt strongly promotes cell survival through phosphorylation of multiple downstream targets including forkhead transcription factor or BCL-2 antagonist of cell death, 49 improved contractile function by inducible expression of Akt in the heart may be owing in part to its prosurvival effects. Collectively, transient activation of Akt signaling in cardiac muscle cells attenuates contractile dysfunction in the failing heart, presumably through multiple mechanisms including modulation of coronary angiogenesis, Ca 2ϩ handling, and cell survival.
In the clinical setting, Akt is not a suitable therapeutic target for patients with heart failure because sustained activation of Akt is deleterious for the heart, presumably through induction of extensive cardiac hypertrophy. 31, 35 Because the positive inotropic effects of Akt can be separated from its growth-promoting effects, downstream substrates of Akt kinase that mediate its cardioprotective effects may be promising therapeutic targets for heart failure.
